About MyGenome Australia

Your genetic blueprint holds the key to understanding and optimizing your health. At MyGenome Australia, we use state-of-the-art genomic testing to provide.
Kathy is a Human Genetics Society of Australasia (HGSA)-certified Clinical Geneticist with more than 16 years of clinical experience in genomics. Currently, she is a senior staff specialist and the founding Head at St Vincent's Clinical Genomics since 2016. In 2016, she established Clinical Genomics as a highly-integrated clinical service with research, education and training opportunities to provide the first clinical whole genome sequencing (WGS) service in the Southern Hemisphere at the time, guided by bioethics principles.
Associate Professor Kathy Wu

Our Story

Kathy is an adult physician scientist in Clinical Genomics, an educator, a genomics equity advocate, and a mother of three. She is a senior staff specialist at St Vincent’s Public and Private Hospitals and St Vincent’s Clinic. She is a past Council Member of the Royal Australasian College of Physicians 2017-2023, and a committee member of the Bioethics Committee of St Vincent’s Hospital 2018-2023, amongst her various other committee roles. Through her affiliations with multiple universities and research institutions, including the UNSW, University of Sydney, University of Notre Dame Australia, Garvan Institute of Medical Research and the George Institute for Global Health, she is committed to teaching and responsible translation of genomics research to inform precision healthcare to improve health outcomes for all Australians. She is passionate about using genomics beyond the traditional role of rare disease diagnosis, to inform disease prevention, personal health optimisation, and risk management. She is committed to education of genomics knowledge as well as ethical and psychosocial issues surrounding genomic medicine.

Kathy is married with three children, aged 10, 14, and 19, plus Cosmo, a 3 year-old Labradoodle; and enjoys reading, knitting, food, and listening to audio books.

Disease Risk Prediction

Identify genetic predispositions for proactive health management.

Medication Response & Metabolism

Optimize treatments through pharmacogenomics.

Reproductive Genetic Health

Reduce the risk of inherited conditions.

Publications

We are proud to contribute to the advancement of medical research through our published work:

2025

  • Davies K, ..Wu KHCet al. Comprehensive characterisation of theRFC1 repeat in an Australian cohort. Submitted toCerebellumMarch 2025.
  • De SousaS,..Wu KHCet al. Australian and New Zealand Joint Society Position Statement on Genetic Testing for Monogenic Diabetes in Adults. Accepted for publication byMJA11 March 2025.
  • De Sousa SMC, Phan JMN, Wells A,Wu KHC and Scott HS. Improving detection of monogenic diabetes through reanalysis of GCK variants of uncertain significance. Accepted for publication, Acta Diabetologica, January 2025.

2024

  • Balasingam D, …andWu KHC. Mainstreaming Genomic Testing for Monogenic Diabetes: Feasibility, Outcome, and Validation Study. Submitted toDiabetes Research and Clinical Practice, December 2024.
  • Rafehi H, ..Wu KHCet al. A prospective trial comparing programmable targeted long-read sequencing and short-read genome sequencing for genetic diagnosis of cerebellar ataxia.Accepted for publication,Genome Research, November 2024.
  • Zochowski Y, Kumar K,...Wu KHC and Tisch S. Case series of cerebellar ataxia with tremor due toSTUB1 (SCA 48) without TBP expansions: further evidence forSTUB1 as a monogenic disease. Accepted for publication,Cerebellum, November 2024.
  • Wang Y,…Wu KHC et al. Fast and Fragile: An Unseen Danger – A case of left atrial cardiomyopathy proceeding left atrial dissection. Accepted for publication,HeartRhythm Case Reports, November 2024.
  • Austin R,..andAustralian Genomics Cardiovascular Disorders Flagship. A multitiered analysis platform for genome sequencing: Design and initial findings of the Australian Genomics Cardiovascular Disorders Flagship.Genet in Med Open 2024; 2: 101842.

2023

  • Moxham R, Tjokrowidjaja A, Devery S, Smyth R, McLean A andWu KHC. Clinical utilities and end-user experience of pharmacogenomics: 39 mo of clinical implementation experience in an Australian hospital setting.World J Med Genet 2023 December 20; 11(4): 39-50.
  • De Sousa SMC,Wu KHC et al. Identification of monogenic diabetes in an Australian cohort using the Exeter maturity‐onset diabetes of the young (MODY) probability calculator and next‐generation sequencing gene panel testing. Published online October 2023.Acta Diabetologica
  • Rafehi H, …Wu KHC,…Bahlo M and Lockhart P. An intronic GAA repeat expansion inFGF14 causes the autosomal dominant adult-onset ataxia SCA50/ATX-FGF14.The American Journal of Human Genetics 2023;110(1):105-119.
  • McLean A, Tchan M, Devery S, Smyth R, Shrestha R, Kumar K, Tomlinson S, Tisch S andWu KHC. Informing a value care model: Lessons from an integrated adult neurogenomics clinic.Intern Med J2023;53(12):2198-2207. doi: 10.1111/imj.16103.
  • Krishnan A,Wu KHCet al. A mitochondrial cytopathy presenting with persistent troponin elevation: Case Report.European Heart Journal – Case Reports 2023;7(4):1-6.

2022

  • Moxham R, Viardot A, Greenfield J andWu KHC. Tip of the iceberg: are we missing undiagnosed patients with Maturity Onset Diabetes of the Young (MODY)?Internal Medicine Journal, 2022 Nov;52(11):2011-2012.https://onlinelibrary.wiley.com/toc/14455994/current
  • Grosz BR,…Wu KHCet al. A novel synonymous KMT2B variant results in aberrant splicing causing dystonia.Molecular Genetics & Genomic Medicine, 2022 May;10(5):e1923.

2021

  • Yap JY, …Wu KHC et al. Intrinsic defects in B cell development and differentiation, T cell exhaustion and altered unconventional T cell generation characterize human adenosine deaminase type 2 deficiency.Journal of Clinical Immunology 2021;41(8):1915-1935.
  • McLean A andWu KHC. Letter to the Editor on: Non-invasive prenatal testing: clinical utility and ethical concerns about recent advances.MJA 2021;215(8):384 e1.
  • Ferkh A, Whalley D,..Wu KHC et al. Left atrial cardiomyopathy with left atrial thrombus despite sinus rhythm, in a patient with severe ventricular cardiomyopathy requiring cardiac transplantation.Cardiovascular Imaging Case Reports (CASE) 2021;5(4):243-251.
  • Austin R, QuinnMCJ,…Wu KHC et al. Investigation of current models of care for genetic heart disease in Australia: A national clinical audit.International Journal of Cardiology 2021 May 1;330:128-134

2020

  • Kumar KR, Cortese A…Wu KHC et al. RFC1 expansions can mimic hereditary sensory neuropathy with cough and Sjogren’s syndrome.Brain 2020;143(10):e82.
  • Yap JY; Gloss B,..Wu KHC,…and CIRCA Consortium. Everolimus-induced remission of classic Kaposi’s sarcoma secondary to cryptic splicing mediated CTLA4 haploinsufficiency.Journal of Clinical Immunology 2020;40(5):774-779.
  • Hussain I, Jin R, Baum H, Greenfield JR, Devery S, Xing C, Hegele RA, Carranza-Leon BG, Linton MF, Vuitch F,Wu KHC, Agarwal AK, Garg A. A Multisystem Progeroid Syndrome with Lipodystrophy, Cardiomyopathy and Proteinuric Nephropathy due to heterozygousLMNAp.R349W Variant.Journal of the Endocrine Society 2020;4(10):1-17. (JIF 7.998, 4 Citations, 52nd percentile, FWCI 0.44)

2019

  • Dai P, Furlong T, Gracie G, Huang M, Tao Yang T,Wu KHC, Danta D, Wong M, Williams A, March L, Hetherington M, Heyworth-Smith D, Phan T, and CIRCA Consortium. Autoinflammation masquerading as autoimmunity in an adult with heterozygous p.E250K PSTPIP1 mutation.Journal of Clinical Immunology 2019;39:519-522.(JIF 8.542, 8 Citations, 83rd percentile, FWCI 1.6
  • Libiano R,Wu KHC, Devery S, Eisman J, Center J. KBG Syndrome Presenting with Brachydactyly Type E.Bone 2019;123:18-22(JIF 4.626, 4 Citations, 45th percentile, FWCI 0.36)
  • Mavaddat N,…..kConFab/AOCS Investigators,….Easton DF. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.American Journal of Human Genetics 2019;104(1):21-34

2017

  • De Sousa SMC, McCabe MJ,Wu K, Roscioli T, Gayevskiy V, Brook K, Rawlings L, Scott HS, Thompson TJ, Earls P, Gill AJ, Cowley MJ, Dinger ME, MaCormack AI. Germline variants in familial pituitary tumour syndrome genes are common in young patients and families with additional endocrine tumours.Eur J Endocrinol.2017 May;176(5):635-644. (JIF 6.558, 23 Citations, 83rd percentile, FWCI 1.6)

2015

  • Wu KHCand Kirk J. Hereditary colorectal cancer: what you need to know.Medicine Today 2015;16(2):20-29

2012

  • Wu KHC, Kohn MR, Turner A, Sillence DO. A common presentation of a rare genetic disorder clinically mimicking primary myopathy.Adolesc Med State Art Rev.2012;23(2):393-403

2006

  • in RJ, Blumenkranz MS, Binkley J,Wu K, Vollrath D. A novel His158Arg mutation in TIMP3 causes a late-onset form of Sorsby fundus dystrophy.Am J Ophthalmol. 2006;142(5):839-48.

Meet Our Team

Lana Steinberg

VP of Customer Success

Lana Steinberg

VP of Customer Success

Lana Steinberg

VP of Customer Success

Lana Steinberg

VP of Customer Success

Lana Steinberg

VP of Customer Success

Lana Steinberg

VP of Customer Success

Frequently Asked Questions

If a person decides to pursue testing following consultation, an once-off fee is charged which covers the entire journey of genomic tests, as well as both pre-test and post-test consultations and care plan. Different tiers of testing packages are offered depending on the person’s specific needs at the time (package pricing can be found here). If a person decides not to proceed with testing, a standard consultation fee is charged following the initial consultation.

There is limited Medicare coverage for certain diagnostic genomic testing (genomic testing undertaken by someone who already exhibits symptoms of a suspected genetic disorder) and limited reproductive carrier screening. The majority of tests included in preventive genomics testing is not covered by either Medicare or private health insurance. Your genomics health professional will discuss this further in the initial consultation.

The doctor’s clinic consultations are claimable through Medicare although the claims are usually capped to certain amounts.

Genomic testing does not impact health insurance. Certain genomic testing may impact risk-based insurance, such as life insurance. Currently, genomic testing for risk prediction undertaken pre-symptomatically (such as in the preventive genomics context), would impact a person’s ability in life insurance policy underwriting up to certain limits based on the current Moratorium in place. This is however rapidly changing, as the Australian government has announced in September 2024 that it will change the law, so that life insurance companies will no longer be able to use genetic/genomic test results to refuse or increase life insurance premiums. This will come into effect when it is written into legislation in the near future. The MGA genetics health professional will provide most up-to-date information in a clinic consultation.

MGA prides in the responsible use of genomics that is evidence-based and tailored to each individual. Through clinical interactions and comprehensive assessment, each client receives the most up-to-date information about genomic testing, appropriate recommendations based on their needs, as well as a comprehensive care plan based on clinical guidelines. There are two-way communications to ensure that all questions and concerns are answered and addressed.

Just as genomics is rapidly evolving, our service and range of testing will also evolve accordingly as we keep abreast with developments in genomic technologies.

A comprehensive clinical assessment is undertaken by certified genetics professionals in a clinic consultation to determine the best testing strategy, which may include a combination of diagnostic and preventive genomic tests. As not every symptom or any positive family history would be related, our experienced geneticist will make a clinical judgement, based on comprehensive assessment, and provide explanations on the recommended tests on the day.

Get started today

Your DNA holds the key to your health future. Book a consultation with MyGenome Australia and take control of your health through the power of genomics.
Genome Concept
MGA Logo
Lorem ipsum dolor sit amet consectetur. Maecenas imperdiet consequat scelerisque amet. Tempus at auctor ut neque a neque. Nisl vitae adipiscing aliquet.

Stay Inspired

Join our newsletter for the latest design tips, trends, and special offers.

Copyright © 2025. MyGenome Australia. All Rights Reserved. Website by Wolf IQ